Compugen Competitors

Kymera Therapeutics (NASDAQ:KYMR) and Compugen (NASDAQ:CGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Kymera Therapeutics and Compugen's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Kymera Therapeutics and Compugen's top-line revenue, earnings per share (EPS) and valuation.

Kymera Therapeutics has higher earnings, but lower revenue than Compugen.

Analyst Ratings

This is a breakdown of current ratings and price targets for Kymera Therapeutics and Compugen, as reported by MarketBeat.com.

Kymera Therapeutics presently has a consensus target price of $50.3333, indicating a potential upside of 9.75%. Compugen has a consensus target price of $20.7143, indicating a potential upside of 153.85%. Given Compugen's stronger consensus rating and higher probable upside, analysts clearly believe Compugen is more favorable than Kymera Therapeutics.

Insider & Institutional Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 63.4% of Compugen shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Compugen beats Kymera Therapeutics on 6 of the 8 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 63.4% of Compugen shares are held by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares BioCryst Pharmaceuticals and Compugen's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares BioCryst Pharmaceuticals and Compugen's top-line revenue, earnings per share (EPS) and valuation.

Compugen has lower revenue, but higher earnings than BioCryst Pharmaceuticals. Compugen is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for BioCryst Pharmaceuticals and Compugen, as reported by MarketBeat.com.

BioCryst Pharmaceuticals presently has a consensus target price of $11.3750, indicating a potential upside of 4.17%. Compugen has a consensus target price of $20.7143, indicating a potential upside of 153.85%. Given Compugen's stronger consensus rating and higher probable upside, analysts clearly believe Compugen is more favorable than BioCryst Pharmaceuticals.

Summary

Compugen beats BioCryst Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

bluebird bio (NASDAQ:BLUE) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares bluebird bio and Compugen's net margins, return on equity and return on assets.

Insider and Institutional Ownership

94.3% of bluebird bio shares are held by institutional investors. Comparatively, 63.4% of Compugen shares are held by institutional investors. 3.6% of bluebird bio shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for bluebird bio and Compugen, as reported by MarketBeat.

bluebird bio presently has a consensus price target of $68.4667, indicating a potential upside of 145.05%. Compugen has a consensus price target of $20.7143, indicating a potential upside of 153.85%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than bluebird bio.

Earnings & Valuation

This table compares bluebird bio and Compugen's gross revenue, earnings per share (EPS) and valuation.

Compugen has lower revenue, but higher earnings than bluebird bio. Compugen is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

bluebird bio has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.

Summary

Compugen beats bluebird bio on 10 of the 14 factors compared between the two stocks.

Compugen (NASDAQ:CGEN) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Compugen and Vericel's net margins, return on equity and return on assets.

Institutional and Insider Ownership

63.4% of Compugen shares are held by institutional investors. Comparatively, 93.1% of Vericel shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 4.3% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Compugen and Vericel, as provided by MarketBeat.com.

Compugen currently has a consensus price target of $20.7143, indicating a potential upside of 153.85%. Vericel has a consensus price target of $49.00, indicating a potential upside of 21.26%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Vericel.

Valuation and Earnings

This table compares Compugen and Vericel's gross revenue, earnings per share and valuation.

Vericel has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Compugen has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500.

Summary

Vericel beats Compugen on 8 of the 14 factors compared between the two stocks.

Compugen (NASDAQ:CGEN) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Compugen and Scholar Rock's net margins, return on equity and return on assets.

Institutional and Insider Ownership

63.4% of Compugen shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 24.6% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Compugen and Scholar Rock, as provided by MarketBeat.com.

Compugen currently has a consensus price target of $20.7143, indicating a potential upside of 153.85%. Scholar Rock has a consensus price target of $61.60, indicating a potential upside of 21.74%. Given Compugen's higher probable upside, analysts plainly believe Compugen is more favorable than Scholar Rock.

Valuation and Earnings

This table compares Compugen and Scholar Rock's gross revenue, earnings per share and valuation.

Compugen has higher earnings, but lower revenue than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Compugen has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.

Summary

Compugen beats Scholar Rock on 9 of the 13 factors compared between the two stocks.

Compugen (NASDAQ:CGEN) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Compugen and Ocugen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

63.4% of Compugen shares are held by institutional investors. Comparatively, 8.5% of Ocugen shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 3.5% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Compugen and Ocugen, as provided by MarketBeat.com.

Compugen currently has a consensus price target of $20.7143, indicating a potential upside of 153.85%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Ocugen.

Valuation and Earnings

This table compares Compugen and Ocugen's gross revenue, earnings per share and valuation.

Ocugen has lower revenue, but higher earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Compugen has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, indicating that its stock price is 256% more volatile than the S&P 500.

Summary

Compugen beats Ocugen on 9 of the 12 factors compared between the two stocks.